PT
Menu
Search
Sections
Home
News
Analysis
Features
Comment & Opinion
Projects
Data Insights
Sectors
Clinical Trials
Drug Manufacturers
Therapy Area
Cardiovascular
Central Nervous System
Immunology
Infectious Disease
Oncology
Respiratory
Pricing and Market Access
Themes
Artificial Intelligence
Corporate Governance
Cloud
Cybersecurity
Environmental Sustainability
Internet of Things
Robotics
Social Responsibility
Covid-19
Insights
Deals
Jobs
Filings
Patents
Social Media
Companies
Company A-Z
Company Categories
Products & Services
Company Releases
White Papers
Videos
Buyer's Guides
Partner Content
Events
Reports
Premium Insights
Excellence Awards
Innovation Rankings
Magazine
Newsletters
GlobalData
About us
Advertise With Us
Contact Us
Our Marketing Solutions
GlobalData Reports
Visit GlobalData
From Our Partners
Optimizing Cell & Gene Therapy Processes
Collaboration and Expertise in Contract Analytical Chemistry
A new generation of CDMO services
Accelerating Biopharmaceutical Innovation
Precision medicine and digital health innovation for disease diagnosis, care and treatment
Enabling process intensification in biopharma manufacturing
The next chapter of clinical trial services
Putting quality first in the pharma supply chain
Pharmaceutical Grade Silicone Manufacturer
Maximising molecule potential
News
Analysis
Sections
Features
Comment & Opinion
Projects
Data Insights
Latest
The top pharmaceutical companies by R&D expenditure
Magazine: Anticipation rises for RSV rollout as positive data emerges
BIOSECURE bill targets more Chinese companies as biotechs and their customers adapt to defunding
Sectors
Sections
Clinical Trials
Drug Manufacturers
Therapy Area
Pricing and Market Access
Latest
Lantern Pharma and Oregon partner to develop cancer treatment
Sentynl acquires Eiger’s Zokinvy for progeria treatment
Lexicon plans another bid for Zynquista in type 1 diabetes
Themes
Sections
Artificial Intelligence
Cloud
Corporate Governance
Cybersecurity
Environmental Sustainability
Internet of Things
Robotics
Social Responsibility
Covid-19
Foreign Direct Investment
Latest
FDA grants RMAT designation to Taysha’s Rett syndrome gene therapy
Moderna reports $1.2bn net loss in Q1 2024
Pfizer’s reported net income declines 44% in Q1 2024
Insights
Sections
Deals
Jobs
Filings
Patents
Social Media
Latest
Moderna reports $1.2bn net loss in Q1 2024
Pfizer’s reported net income declines 44% in Q1 2024
Eli Lilly reports 67% increase in Q1 2024 net income
Companies
Sections
Company A-Z
Company Categories
Products & Services
Company Releases
White Papers
Videos
Buyer's Guides
Partner Content
Latest
Optimisation in operations: from theory to practice
ePRO vs eCOA: Understanding the nuances in clinical trials
Duchenne Muscular Dystrophy: the global clinical trials landscape 2024
Events
Buy Reports
Newsletters
PT
All articles by Marco Guzman Barrios
Marco Guzman Barrios
View more
